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With great interest we read the article by Sandborn et al. (Gut 2007;56:1232) about 
maintenance therapy of Crohn’s disease with adalimumab and the recent publication 
by Viget et al on opportunistic infections in patients with inflammatory bowel disease.1 
In their series including 276 patients, Sandborn et al. note no severe infectious 
complications apart from upper respiratory tract infections. Noteworthy, no cases of 
aspergillosis or other opportunistic infections were reported. 
Unfortunately, serious infections are a well known problem of TNF-α antibody 
therapies. Here, we present a case report of a 69 year old female patient with a long 
history of stenosing Crohn’s disease. The patient began to have fever, dyspnea, and 
a productive cough five days after she took a subcutaneous injection of 40 mg 
adalimumab (Humira®), which necessitated hospitalisation. She had been on a 
stable treatment with adalimumab 40mg s.c. every other week for more than one 
year. At a routine outpatient consultation two weeks prior to admission, she was in 
good health with no signs of inflammation or neutropenia documented in the 
laboratory results. She was on adalimumab monotherapy and her medication did not 
include corticosteroids or other immunomodulating drugs. On admission the patient 
was tachydyspnoic, tachycardic and hypotensive but not febrile. Her chest 
radiography showed massive bilateral infiltrates and laboratory examination revealed 
an elevated C-reactive protein and leukocytosis. Within 12 hours after admission, 
respiratory insufficiency developed. Ventilatory support was needed to achieve 
adequate oxygenation. A bronchoscopy was performed, which showed white 
coverings, histologically corresponding to invasive aspergillosis. The situation was 
complicated by a pre-existing renal insufficiency and a chronic metabolic acidosis. 
Despite intensive care treatment including antibiotics, fungostatic therapy, vasoactive 
drugs and hemofiltration the patient died two days after admission. 
Our patient had no known risk factors associated with invasive aspergillosis. 
She had no neutropenia, nor did she take any corticosteroids or other 
immunosuppressive drugs during the twelve months before the infection. She had 
been a non-smoker, had not used marijuana, and had not had a prior influenza 
infection or any known exposure to aspergillus. Therefore, an association with the 
TNF-α blocker therapy is highly probable.  
Infections are a well known complication of all TNF-α antibodies. In a recent 
review Tsiodras and colleagues have summarized fungal infections after TNF-α 
blockade therapy. Out of 281 cases of invasive fungal infections 11 cases (4%) were 
associated with adalimumab (compared to 80 % associated with infliximab and 16% 
with etanercept).2 For the two cases with aspergillosis on adalimumab no further data 
was available in this review.2 Whereas invasive pulmonary aspergillosis is associated 
with infliximab therapy3 it has to our best knowledge not been described for other 
anti-TNF-α antibodies so far. TNF- α inhibition can increase susceptibility to invasive 
fungal infections trough inhibition of interferon-γ production, a decreased expression 
of pattern-recognition receptors and trough leukocyte apoptosis.4 
With this fatal case we would like to support the observations that the use of 
antibodies against TNF-α including the new agents like adalimumab increases the 
risk of serious opportunistic infections trough inhibition of an adequate TNF-α 
response. Clinicians should have a high level of suspicion for fast diagnosis and 
treatment of fungal disease in patients with TNF-α blockers. 
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